GlassScriptPhysician profile
Suzanne M Brant
NPI 1225267677
$2,995.51
in general payments reported to CMS, 2019-2025
11 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $134 · 2021: $630 · 2022: $534 · 2023: $474 · 2024: $586 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,411.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,007.49 | 2019-2025 | Precision 1, Total30, Dailies Total1 |
| Coopervision INC. | $680.08 | 2021-2025 | Myday Contact Lens, Clariti Contact Lens, Biofinity Contact Lens |
| Sun Pharmaceutical Industries INC. | $325.36 | 2020-2022 | |
| Glaukos Corporation | $285.45 | 2024-2025 | Istent Infinite |
| Bausch & Lomb Americas INC. | $260.22 | 2022-2025 | Infuse, Miebo, Xiidra |
| Johnson & Johnson Vision Care, INC. | $169.04 | 2019-2022 | |
| Abbvie INC. | $162.43 | 2022-2024 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $38.48 | 2025 | Xdemvy |
| Biotissue Holdings INC. | $23.12 | 2023 | |
| Maculogix, INC. | $5.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Brant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.